Novo Nordisk A/S (TSX:NOVO)
Canada flag Canada · Delayed Price · Currency is CAD
18.38
+0.73 (4.14%)
Nov 13, 2026, 4:00 PM EST

Novo Nordisk Financials Overview

Millions DKK. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
333,650309,064290,403232,261176,954140,800
Revenue Growth
5.72%6.43%25.03%31.25%25.68%10.91%
Gross Profit
278,039254,687246,843196,942148,530117,142
Operating Income
169,423140,618138,901104,69875,61859,217
Net Income
113,177102,434100,98883,68355,52547,757
Earnings Per Share
25.4923.0322.6318.6212.2210.37
EPS Growth
9.24%1.77%21.54%52.37%17.84%15.16%

Revenue by Segment

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Ozempic Pill / Rybelsus
20,04122,09323,30118,75011,2994,838
Ozempic Injectable
120,731127,089120,34295,71859,75033,705
Victoza
1,0193,0205,4828,66412,32215,054
Long-Acting Insulin
17,72318,75519,09514,90516,74118,064
Premix Insulin
10,11310,31510,7899,57410,56211,203
Fast-Acting Insulin
17,90518,58318,52215,94917,46317,687
Human Insulin
4,5115,4846,9677,5948,1869,052
Other Diabetes Care
2,2171,7702,1202,3123,2253,594
Wegovy Injectable
79,99079,10658,20631,3436,1881,386
Saxenda
1,7973,2416,94010,28910,6767,014
Rare Blood Disorders
11,60311,95512,13811,77611,70610,217
Rare Endocrine Disorders
6,5135,9594,9933,8367,1387,303
Other Rare Disease
1,8591,6941,5081,5511,6981,683
Revenue (Total)
333,650309,064290,403232,261176,954140,800

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
46,35226,96226,30830,23023,57417,485
Total Debt
134,480130,958102,78727,00625,78426,645
Net Cash (Debt)
-88,128-103,996-76,4793,224-2,210-9,160
Net Cash Growth
------
Net Cash Per Share
-19.85-23.38-17.140.72-0.49-1.99

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
127,325119,102120,968108,90878,88755,000
Capital Expenditures
-55,642-60,140-47,164-25,806-12,146-6,335
Free Cash Flow
71,68358,96273,80483,10266,74148,665
Free Cash Flow Growth
6.58%-20.11%-11.19%24.51%37.14%5.50%

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
83.33%82.41%85.00%84.79%83.94%83.20%
Operating Margin
50.78%45.50%47.83%45.08%42.73%42.06%
Pretax Margin
43.36%42.24%43.80%45.07%39.03%41.96%
Profit Margin
33.92%33.14%34.77%36.03%31.38%33.92%
FCF Margin
21.48%19.08%25.41%35.78%37.72%34.56%

Dividends

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Dividend Per Share
0.69411.70011.4009.4006.2005.200
Dividend Per Share Growth
0%2.63%21.28%51.61%19.23%14.29%
Dividend Yield
3.78%3.60%1.83%1.35%1.32%1.42%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
10.9214.1127.4537.1938.1635.07
P/FCF Ratio
16.7024.5137.5637.4531.7534.42
PS Ratio
3.594.689.5513.4011.9711.90